Mitchell Gold M.d.

Mitchell Gold M.D. has extensive experience in the biotechnology and healthcare sectors, currently serving as a Board Member at Attovia Therapeutics since July 2024 and as a Managing Partner at Alpine BioVentures since September 2013. Gold co-founded and held the positions of Executive Chairman and CEO at Alpine Immune Sciences from January 2015 to July 2024, and was the Founder and Chairman of Alpine Biosciences from August 2012 to August 2014. Previous roles include Chairman of the Board at Dendreon Corporation from February 2012 to February 2013 and President and CEO at Dendreon from May 2001 to February 2012. Gold also served as VP of Business Development at Data Critical, which was sold to GE Medical, and as President and CEO of Elixis, sold to Data Critical in 2000. Educational background includes an MD from the University of Washington - School of Medicine and a BS in Biology from the University of Wisconsin-Madison.